Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease

Parkinsonism and Related Disorders

Volumn 15, Issue 2, 2009, Pages 138-143

  Scigliano, Giulio ^a   Ronchetti, Gabriele ^b   Girotti, Floriano ^a   Musicco, Massimo ^c  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

Autonomic nervous system; Cholesterol; Diabetes; Hypertension; Parkinson's disease; Sympathetic nervous system; Triglycerides; Vascular risk factors

Indexed keywords

CHOLESTEROL; GLUCOSE; LEVODOPA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPATHETIC FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK; SYMPATHETIC NERVOUS SYSTEM; TRIGLYCERIDES; VASCULAR DISEASES;

EID: 58749099484     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.036     Document Type: Article

References (28)

1. Laverty R. Catecholamines: role in health and disease. Drugs 16 (1978) 418-440
2. Rahn K.H., Barenbrock M., and Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. J Hypertens 17 S 3 (1999) 11-14
3. Jamerson K.A., Julius S., Gudbrandsson D., Andersson O., and Brant D.O. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21 5 (1993) 618-623
4. Day J.L., Metcalfe J., and Simpson C.N. Adrenergic mechanism in control of plasma lipid concentrations. BMJ 284 (1982) 1145-1148
5. Mannelli M., Pupili C., Lanzillotti R., Ianni L., Bellini F., and Sergio M. Role of endogenous dopamine in modulating sympathetic-adrenal activity in humans. Hypertens Res 18 Suppl 1 (1995) S79-S86
6. Saito I., Kawabe H., Hasegawa C., Iwaida Y., Yamakawa H., Saruta T., et al. Effect of L-dopa in young patients with hypertension. Angiology 42 (1991) 691-695
7. Ben-Shlomo Y., and Marmont M.G. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?. J Neurol Neurosurg Psychiatry 58 (1995) 293-299
8. Struck L.K., Rodnitzky R.L., and Dobson J.K. Stroke and its modification in Parkinson's disease. Stroke 21 (1990) 1395-1399
9. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
10. Brogden R.N., Speight T.M., and Avery G.S. Levodopa. a review of its pharmacological properties and therapeutic uses with particular reference to parkinsonism. Drugs 2 4 (1971) 262-400
11. Watanabe A.M., Chase T.N., and Cardon P.V. Effect of L-dopa alone and in combination with extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther 11 (1970) 740-746
12. Dingemanse J., Kleinbloesem C.H., Zurcher G., Wood N.D., and Crevoisier C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 44 (1997) 41-48
13. Whitsett T.L., Halushka P.V., and Goldberg L.I. Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res 27 (1970) 561-570
14. Murphy M.B. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 14 (2000) S47-S50
15. Ahren B., Wierup N., and Sundler F. Neuropeptides and the regulation of islet function. Diabetes 55 Suppl 2 (2006) 98-107
16. Attvall S., Fowelin J., von Schenck H., Lager I., and Smith U. Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia-evidence for the importance of beta-adrenergic stimulation. Diabetologia 30 9 (1987) 691-697
17. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43 5 (2000) 533-549
18. Kamath V., Jones C.N., Yip J.C., Varasteh B.B., Cincotta A.H., Reaven G.M., et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 20 11 (1997) 1697-1701
19. Pijl H., Ohashi S., Matsuda M., Miyazaki Y., Mahankali A., Kumar V., et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23 8 (2000) 1154-1161
20. Cincotta A.H., Meier A.H., and Cincotta Jr. M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Invest Drugs 8 10 (1999) 1683-1707
21. Katholi R.E. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 245 1 (1983) 1-14
22. Barbeau A., Gillo-Joffroy L., Boucher R., Nowaczynskc W., and Genest J. Renin-aldosterone system in Parkinson's disease. Science 165 (1969) 291-292
23. Barbieri C., Caldara R., Ferrari C., Crossignani R.M., and Recchia M. Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man. Clin Sci (Lond) 61 (1981) 187-190
24. Goldberg L.I., and Rajfer S.I. Dopamine receptors: applications in clinical cardiology. Circulation 72 (1985) 245-248
25. Leblanc H., Lachelin G.C., Abu-Fadil S., and Yen S.S. The effect of dopamine infusion on insulin and glucagon secretion in man. J Clin Endocrinol Metab 44 1 (1977) 196-198
26. Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G., and Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37 (2006) 1184-1188
27. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattström L.E., Ueland P.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277 (1997) 1775-1781
28. Rogers J.D., Sanchez-Saffon A., Frol A.B., and Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60 (2003) 59-64